Policy changes Backwork has recorded, newest first. The most recent change on record is from October 24, 2026. Changes appear here after Backwork reviews and applies a refresh, so this page can trail the payers’ own sites.
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
86,510 on record
| Recorded | Payer | Policy | Change |
|---|---|---|---|
| May 17, 2026 | BlueCross BlueShield of Tennessee | Automated Percutaneous and Endoscopic Discectomy | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Ustekinumab and Associated Biosimilars | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Hematopoietic Stem-Cell Transplantation for Malignant Astrocytomas and Gliomas | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Use of a Medial Knee Implantable Shock Absorber | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Autologous Chondrocyte Implantation (ACI) | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Unicondylar Interpositional Spacer as a Treatment of Unicompartmental Arthritis of the Knee | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Auricular Electrostimulation | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Ultrasonic Osteogenesis Stimulator | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Ultrafiltration in Decompensated Heart Failure | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Sensory and Auditory Integration Therapies | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Ublituximab-xiiy | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Obecabtagene Autoleucel (Aucatzyl) | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Tumor Treating Fields (TTF) Therapy | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Avacincaptad Pegol (Izervay) | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Triamcinolone acetonide | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Atidarsagene Autotemcel (Lenmeldy) | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Treatment of Tinnitus | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Treatment of Hyperhidrosis | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Atezolizumab and Hyaluronidase-tqjs (Tecentria Hybreza) | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Treatment of Congenital Athymia | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Atezolizumab (Tecentriq) | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Treatment for Duchenne Muscular Dystrophy | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Calaspargase Pegol-mknl (Asparlas) | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Transcutaneous Electrical Stimulation (TENS) and Transcutaneous Afferent Patterned Stimulation | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Asparaginase Erwinia chrysanthemi (recombinant)-rywn (Rylaze) | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Transcranial Magnetic Stimulation as a Treatment of Depression and Other Psychiatric/Neurologic Disorders | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Artificial Intervertebral Disc | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Transcatheter Tricuspid Valve Repair or Replacement | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Transcatheter Pulmonary Valve Implantation | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Diagnosis and Treatment of Sacroiliac Joint Pain | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Transcatheter Mitral Valve Repair or Replacement | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Subtalar Arthroereisis | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Transcatheter Arterial Chemoembolization to Treat Primary or Metastatic Liver Malignancies | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | End Diastolic Pneumatic Compression Boot as a Treatment of Peripheral Vascular Disease or Lymphedema | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Transcatheter Aortic-Valve Implantation for Aortic Stenosis | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Nelarabine (Arranon) | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Transanal Radiofrequency (RF) Treatment of Fecal Incontinence | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Transanal Endoscopic Microsurgery | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Darbepoetin Alfa (Aranesp) | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Tocilizumab and Associated Biosimilar(s) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Aqueous Shunts and Stents for Glaucoma | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Tildrakizumab-asmn | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Motixafortide (Aphexda) | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Tibial Nerve Stimulation | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Ovarian Cancer Tumor Markers | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Thermography | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Therapeutic Embolization and Vessel Occlusion to Treat Pelvic Conditions | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Nogapendekin Alfa-Inbakicept-pmln (Anktiva) | Criteria changed |
| May 17, 2026 | BCBS Oklahoma | Tezepelumab-ekko | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Total Ankle Replacement | Criteria changed |